Literature DB >> 26605996

Bone mineralization-dependent craniosynostosis and craniofacial shape abnormalities in the mouse model of infantile hypophosphatasia.

John Durussel1, Jin Liu1, Cassandra Campbell1, Hwa K Nam1, Nan E Hatch1.   

Abstract

BACKGROUND: Inactivating mutations in tissue-nonspecific alkaline phosphatase (TNAP) cause hypophosphatasia (HPP), which is commonly characterized by decreased bone mineralization. Infants and mice with HPP can also develop craniosynostosis and craniofacial shape abnormalities, although the mechanism by which TNAP deficiency causes these craniofacial defects is not yet known. Manifestations of HPP are heterogeneous in severity, and evidence from the literature suggests that much of this variability is mutation dependent. Here, we performed a comprehensive analysis of craniosynostosis and craniofacial shape variation in the Alpl(-/-) mouse model of murine HPP as an initial step toward better understanding penetrance of the HPP craniofacial phenotype.
RESULTS: Despite similar deficiencies in alkaline phosphatase, Alpl(-/-) mice develop craniosynostosis and a brachycephalic/acrocephalic craniofacial shape of variable penetrance. Only those Alpl(-/-) mice with a severe bone hypomineralization defect develop craniosynostosis and an abnormal craniofacial shape.
CONCLUSIONS: These results indicate that variability of the HPP phenotype is not entirely dependent upon the type of genetic mutation and level of residual alkaline phosphatase activity. Additionally, despite a severity continuum of the bone hypomineralization phenotype, craniofacial skeletal shape abnormalities and craniosynostosis occur only in the context of severely diminished bone mineralization in the Alpl(-/-) mouse model of HPP.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  bone; craniofacial; craniosynostosis; hypophosphatasia; mineralization; skull

Mesh:

Substances:

Year:  2015        PMID: 26605996     DOI: 10.1002/dvdy.24370

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  5 in total

1.  Anabolic actions of parathyroid hormone in a hypophosphatasia mouse model.

Authors:  Laurie K McCauley; Nan E Hatch; Amy J Koh; Hwa Kyung Nam; Megan N Michalski; Justin Do
Journal:  Osteoporos Int       Date:  2022-07-23       Impact factor: 5.071

Review 2.  Alkaline Phosphatase Replacement Therapy for Hypophosphatasia in Development and Practice.

Authors:  S A Bowden; B L Foster
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 3.  Suitability and limitations of mesenchymal stem cells to elucidate human bone illness.

Authors:  Izaskun Mitxitorena; Arantza Infante; Blanca Gener; Clara I Rodríguez
Journal:  World J Stem Cells       Date:  2019-09-26       Impact factor: 5.326

Review 4.  Tissue-Nonspecific Alkaline Phosphatase-A Gatekeeper of Physiological Conditions in Health and a Modulator of Biological Environments in Disease.

Authors:  Daniel Liedtke; Christine Hofmann; Franz Jakob; Eva Klopocki; Stephanie Graser
Journal:  Biomolecules       Date:  2020-12-08

Review 5.  Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy.

Authors:  Sasigarn A Bowden; Brian L Foster
Journal:  Drug Des Devel Ther       Date:  2018-09-24       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.